Latest News

Latest News

Idelalisib gains SMC approval for NHS Scotland use + early access programme

Idelalisib (Zydelig) has been accepted for restricted use by NHS Scotland. you can read more & access the full guidance PDF from the download on the SMC website.  

CLLSA have participated in the consultation process,  it is rewarding to see this now gain approval.  

SMC intitial guidance details:

following a full submission

Ofatumumab plus Chlorambucil and Obinutuzimab plus Chlorambucil Gain NICE preliminary approval for NHS treatment of CLL

CLLSA at NICE and preliminary NICE guidance for two new CLL treatments.

The CLLSA regulatory appraisals volunteer group are participating in six NICE consultations. CLLSA representatives commented on the following NICE documents and attended the Scope, Appraisal workshops and participated on appraisal committees to date this year this has resulted in the excellent news that two new treatments have already received preliminary recommendation by NICE for NHS treatment of CLL in England and Wales: